Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2006.080234v1, 2007; 10.1373/clinchem.2006.080234
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.080234v1
53/7/1289    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Emdin, M.
Right arrow Articles by Clerico, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Emdin, M.
Right arrow Articles by Clerico, A.

Received on September 16, 2006
Accepted on April 23, 2007

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure

Michele Emdin 1*, Claudio Passino 2, Concetta Prontera 1, Marianna Fontana 1, Roberta Poletti 1, Alessandra Gabutti 1, Chiara Mammini 1, Alberto Giannoni 1, Luc Zyw 1, Giancarlo Zucchelli 1, Aldo Clerico 2

1 CNR Institute of Clinical Physiology, Cardiovascular Medicine Department and Cardiovascular Endocrinology Laboratory, Pisa, Italy
2 CNR Institute of Clinical Physiology, Cardiovascular Medicine Department and Cardiovascular Endocrinology Laboratory, Pisa, Italy, and Scuola Superiore S. Anna, Pisa, Italy

* To whom correspondence should be addressed. E-mail: emdin{at}ifc.cnr.it.

Background: We compared the diagnostic accuracy of brain natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP) for diagnosis of preclinical and mild heart failure (HF).

Methods: We assayed plasma NT-proBNP and BNP in 182 healthy controls and in a prospective cohort of 820 HF patients divided according to the American Heart Association/American College of Cardiology classification. These included 86 patients in stage A [mean (SE) ejection fraction 61% (1%); mean (SE) age 47 (2) years], 255 in stage B [65% (2%); 62 (1) years], 420 patients in stage C [35% (1%); 68 (1) years] and 59 in stage D [25% (1%)]. Diagnostic accuracies of BNP and NT-proBNP were evaluated by receiver operating curve analysis, and a multivariate linear regression model was applied to predict HF staging.

Results: Median BNP and NT-proBNP concentrations increased from stage A to D 57-fold and 107-fold, respectively. Both assays were accurate (P <0.001) in separating stage B from controls or stage A, and stage C from controls or stage A or B. NT-proBNP was more accurate (P <0.001) than BNP in differentiating stage C from stages A and B patients and controls and was a better predictor of HF classification in a model including age, sex, and renal function (P <0.001).

Conclusions: Monitoring BNP or NT-proBNP enabled identification of asymptomatic patients at risk for the development of HF. NT-proBNP showed better accuracy than BNP for identifying mild HF.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.